Stock KALV KALVISTA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Market Closed - Nasdaq
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
11.55 USD -1.45% Intraday chart for KalVista Pharmaceuticals, Inc. -2.28% -5.71%
06-18 KalVista Pharmaceuticals Submits New Drug Application to FDA for Investigational Hereditary Angioedema Treatment MT
06-18 KalVista Seeks FDA OK of Sebetralstat for Hereditary-Angioedema Attacks DJ

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
BU
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
BU
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
BU
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
BU
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
BU
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
BU
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
KalVista Pharmaceuticals : Corporate Presentation May 2024
PU
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
BU
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
BU
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
BU
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
BU
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine Designation for Sebetralstat
AQ
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
BU
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KALV Stock
  4. News KalVista Pharmaceuticals, Inc.
  5. Press Releases